Article: Co-circulation of seasonal influenza A(H1N1)pdm09, A(H3N2) and B/Victoria lineage viruses with further genetic diversification, EU/EEA, 2022/23 influenza season

BackgroundInfluenza viruses can cause large seasonal epidemics with high healthcare impact and severity as they continually change their virological properties such as genetic makeup over time.AimWe aimed to monitor the characteristics of circulating influenza viruses over the 2022/23 influenza season in the EU/EEA countries. In addition, we wanted to compare how closely the circulating viruses resemble the viral components selected for seasonal influenza vaccines, and whether the circulating viruses had acquired resistance to commonly used antiviral drugs.MethodsWe performed a descriptive analysis of the influenza virus detections and characterisations reported by National Influenza Centres (NIC) from the 30 EU/EEA countries from week 40/2022 to week 39/2023 to The European Surveillance System (TESSy) as part of the Global Influenza Surveillance and Response System (GISRS).ResultsIn the EU/EEA countries, the 2022/23 influenza season was characterised by co-circulation of A(H1N1)pdm09, A(H3N2) and B/Victoria-lineage viruses. The genetic evolution of these viruses continued and clade 6B.1A.5a.2a of A(H1N1)pdm09, 3C.2a1b.2a.2b of A(H3N2) and V1A.3a.2 of B/Victoria viruses dominated. Influenza B/Yamagata-lineage viruses were not reported.DiscussionThe World Health Organization (WHO) vaccine composition recommendation for the northern hemisphere 2023/24 season reflects the European virus evolution, with a change of the A(H1N1)pdm09 component, while keeping the A(H3N2) and B/Victoria-lineage components unchanged.

Citing Articles

Diagnostic Significance of Influenza Symptoms and Signs, and Their Variation by Type/Subtype, in Outpatients Aged ≥ 15 Years: Novi Sad, Serbia.

Miljkovic A, Patic A, Petrovic V, Nikolic N, Kovacevic G, Pustahija T Viruses. 2025; 17(2).

PMID: 40007027 PMC: 11860240. DOI: 10.3390/v17020272.

References

1.

Melidou A, Hungnes O, Pereyaslov D, Adlhoch C, Segaloff H, Robesyn E . Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019. Vaccine. 2020; 38(35):5707-5717. DOI: 10.1016/j.vaccine.2020.06.031. View

2.

Johnson F . Transport of viral specimens. Clin Microbiol Rev. 1990; 3(2):120-31. PMC: 358147. DOI: 10.1128/CMR.3.2.120. View

3.

Kissling E, Maurel M, Emborg H, Whitaker H, McMenamin J, Howard J . Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023; 28(21). PMC: 10283457. DOI: 10.2807/1560-7917.ES.2023.28.21.2300116. View

4.

Adlhoch C, Mook P, Lamb F, Ferland L, Melidou A, Amato-Gauci A . Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill. 2021; 26(11). PMC: 7976381. DOI: 10.2807/1560-7917.ES.2021.26.11.2100221. View

5.

Melidou A, Kodmon C, Nahapetyan K, Kraus A, Alm E, Adlhoch C . Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22. Euro Surveill. 2022; 27(15). PMC: 9012087. DOI: 10.2807/1560-7917.ES.2022.27.15.2200255. View

6.

Koutsakos M, Wheatley A, Laurie K, Kent S, Rockman S . Influenza lineage extinction during the COVID-19 pandemic?. Nat Rev Microbiol. 2021; 19(12):741-742. PMC: 8477979. DOI: 10.1038/s41579-021-00642-4. View

7.

Bhat Y . Influenza B infections in children: A review. World J Clin Pediatr. 2021; 9(3):44-52. PMC: 7769779. DOI: 10.5409/wjcp.v9.i3.44. View

8.

McLean H, Petrie J, Hanson K, Meece J, Rolfes M, Sylvester G . Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023; 72(8):201-205. PMC: 9949852. DOI: 10.15585/mmwr.mm7208a1. View

9.

Skowronski D, Chuang E, Sabaiduc S, Kaweski S, Kim S, Dickinson J . Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23. Euro Surveill. 2023; 28(5). PMC: 9896608. DOI: 10.2807/1560-7917.ES.2023.28.5.2300043. View

10.

Elbe S, Buckland-Merrett G . Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2019; 1(1):33-46. PMC: 6607375. DOI: 10.1002/gch2.1018. View

11.

Paget J, Caini S, Riccio M, van Waarden W, Meijer A . Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines?. Euro Surveill. 2022; 27(39). PMC: 9524051. DOI: 10.2807/1560-7917.ES.2022.27.39.2200753. View

Co-circulation of Seasonal Influenza A(H1N1)pdm09, A(H3N2) and B/Victoria Lineage Viruses with Further Genetic Diversification, EU/EEA, 2022/23 Influenza Season